TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05903833: Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Sponsor: AGO Research GmbH · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$508,200

Rescue Site Savings

+$323,400

Unlock Full NCT05903833 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05903833 Rescue Dossier →